This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
The efficacy of CRESEMBA® has been proven in clinical practice1–4
CRESEMBA® has been used in over 91,000 people5 and has proven effective against invasive aspergillosis and mucormycosis in clinical practice.1–4
In a real-world retrospective study in invasive aspergillosis, CRESEMBA® was associated with higher survival rates than other antifungals.6
CRESEMBA® has proven effective in different patient populations and infection sites in clinical practice.3
In a retrospective US cohort study, CRESEMBA® achieved good treatment responses in varied patient groups, including those receiving prior azole prophylaxis.3
Adapted from reference 3.
a. The fungal pathogen was identified in 38 patients, Aspergillus (n=17) and Mucorales (n=10) being the most common. Partial and complete response were defined in accordance with the MSG/EORTC consensus criteria.
Adapted from reference 3.
a. The fungal pathogen was identified in 38 patients, Aspergillus (n=17) and Mucorales (n=10) being the most common. Partial and complete response were defined in accordance with the MSG/EORTC consensus criteria.
AmB, amphotericin B; EORTC, European Organization for Research and Treatment of Cancer; IA, invasive aspergillosis; MSG, Mycoses Study Group.
Prescribing Information:
References:
PP-CRB-IND-0472 July 2022
Example
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.